740 results on '"Michel, M. C."'
Search Results
2. Het autonome zenuwstelsel
3. Beeinflussen Medikamente gegen das benigne Prostatasyndrom Stimmung oder Kognition?
4. Introduction
5. NPY Receptor Subtypes and Their Signal Transduction
6. Neuropeptide Y and the Kidney
7. Impact of diabetes, hypertension, and their combination on basal symptoms and treatment responses in overactive bladder patients
8. Receptor systems in the non-failing human heart
9. THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: Overview
10. Plutonium-244: Confirmation as an Extinct Radioactivity
11. Uncovering A Role Of Beta 3-Adrenoceptors In Control Of Bladder Size
12. An observational study of patient satisfaction with fesoterodine in the treatment of overactive bladder: effects of additional educational material
13. Atypical β-adrenergic receptors in urinary bladder
14. MicroHip: a minimally invasive procedure for total hip replacement surgery. A modified Smith-Peterson approach
15. Benigne Prostatahyperplasie
16. Anticholinergika bei überaktiver Blase: Spielt Subtypselektivität eine Rolle?
17. Medikamentöse Therapie der Harninkontinenz
18. Die medikamenteninduzierte Dysfunktion der Harnblase
19. Neue pharmakologische Therapiekonzepte bei instabiler Blase
20. Does concomitant diabetes affect treatment responses in overactive bladder patients?
21. Autonomic nervous control of the urinary bladder
22. α1-Rezeptorenblockade zur Therapie des BPH-Syndroms Richtige Dosierung für optimale Wirkung: Richtige Dosierung für optimale Wirkung
23. Is bradykinin a mediator of renal neuropeptide Y effects?
24. Differential regulation of human α1-adrenoceptor subtypes
25. Sildenafil (Viagra®) • Tolerability, contraindications and drug interactions: Verträglichkeit, Kontraindikationen, Arzneimittelinteraktionen
26. Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients?
27. Renal effects of neuropeptide Y
28. Comparison of human α1-adrenoceptor subtype coupling to protein kinase C activation and related signalling pathways
29. Urinary urgency – translating the evidence base into daily clinical practice
30. How are women with SUI-symptoms treated with duloxetine in real life practice? – Preliminary results from a large observational study in Germany
31. Can open-label studies demonstrate efficacy in improving sexual function?
32. Pitfalls in the normalization of real-time polymerase chain reaction data
33. The Y1 antagonist BIBP 3226 inhibits potentiation of methoxamine-induced vasoconstriction by neuropeptide Y
34. A comparison of EMIT and FPIA methods for the detection of cyclosporin A blood levels: does impaired liver function make a difference?
35. α2-Adrenoceptors in opossum kidney cells couple to stimulation of mitogen-activated protein kinase independently of adenylyl cyclase inhibition
36. Comparison of adrenoceptor subtype expression in porcine and human bladder and prostate
37. Renovascular and tubular effects of neuropeptide Y are discriminated by PP56 (D-myo-inositol 1,2,6-triphosphate) in anaesthetized rats
38. Influence of adrenoceptor and muscarinic receptor blockade on the cardiovascular effects of exogenous noradrenaline and of endogenous noradrenaline released by infused tyramine
39. NPY Receptor Subtypes and Their Signal Transduction
40. Neuropeptide Y and the Kidney
41. Modulation of sphingolipid metabolism orchestrates vascular contractility in isolated carotid arteries from spontaneously hypertensive rats: S14.C001
42. Sphingosine-1-phosphate signalling in rat bladder smooth muscle cells: S6.C002
43. Functional selectivity at the human sphingosine-1-phosphate type 3 receptor: S2.C001
44. α1-Adrenoceptors and ejaculatory function
45. Effects of sphingosine-1-phosphate and sphingosylphosphorylcholine on intracellular Ca2+ and cell death in prostate cancer cell lines
46. Effect of short-term outlet obstruction on rat bladder nerve density and contractility
47. BML-241 fails to display selective antagonism at the sphingosine-1-phosphate receptor, S1P3
48. Safety and tolerability of duloxetine in women with stress urinary incontinence
49. Lack of desensitization of α-and β-adrenoceptor function during chronic treatment of healthy volunteers with ibopamine, an orally active dopamine receptor agonist
50. Is cyclic AMP formation desensitized in patients with end-stage renal failure?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.